In a report released today, Carter Gould from Barclays maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price target of $73.00. The company’s shares closed yesterday at $52.73.
Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Biogen, and Regeneron. According to TipRanks, Gould has an average return of 8.2% and a 54.01% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $79.70 average price target.
Based on Arcellx Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $63.15 million and a net profit of $19.84 million. In comparison, last year the company had a GAAP net loss of $38.99 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcellx Inc (ACLX) Company Description:
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
